University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Christina Yau, PhD

Christina Yau, PhD

Assistant Adjunct Professor, Dept. of Surgery, UCSF

Cancer Center Program Memberships

Breast Oncology

Education

UC Berkeley, B.S, 2000, Bioengineering
Joint Program at UC Berkeley and UCSF, Ph.D, 2008, Bioengineering
UC Berkeley, 2008-2009, Biostatistics
Buck Institute for Research on Aging, 2008-2010, Breast Cancer Biology


Professional Experience

  • 2000
    Graduate Student Instructor, Biology 1B, UC Berkeley
  • 2001-2003
    Graduate Student Researcher, UCSF
  • 2003-2008
    Graduate Student Researcher, Buck Institute for Research on Aging
  • 2008-2009
    Joint Postdoctoral Research Fellow, Buck Institute and UC Berkeley 
  • 2009-2010
    Postdoctoral Research Fellow, Buck Institute for Research on Aging
  • 2010-2012
    Staff Scientist, Buck Institute for Research on Aging
  • 2010-2012
    Staff Research Associate, UCSF Comprehensive Cancer Center
  • 2012-2016
    Senior Staff Scientist, Buck Institute for Research on Aging
  • 2012-present
    Adjunct Assistant Professor, UCSF Comprehensive Cancer Center

Honors & Awards

  • 2008
    UCSF Breast Oncology Program Scientific Retreat, Best Poster Presentation Award
  • 2008
    American Federation for Aging Research AFAR-GE Healthcare Junior Investigator Award
  • 2009
    AACR-Susan G. Komen for the Cure Scholar-in-Training Award, AACR 100th Annual Meeting
  • 2009
    AACR Translational Research Scholar Award, San Antonio Breast Cancer Symposium
  • 2014
    UCSF Breast Oncology Program Scientific Retreat, Best Poster Presentation Award

Selected Publications

  1. Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res. 2017 Aug 25; 19(1):99.
    View on PubMed
  2. van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Res Treat. 2017 Aug 04.
    View on PubMed
  3. Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):129-138.
    View on PubMed
  4. Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):181-191.
    View on PubMed
  5. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 Mar 16; 543(7645):378-384.
    View on PubMed
  6. Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. Breast Cancer Res Treat. 2016 Nov 4.
    View on PubMed
  7. Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016 Nov; 22(11):1321-1329.
    View on PubMed
  8. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 7; 375(1):23-34.
    View on PubMed
  9. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7; 375(1):11-22.
    View on PubMed
  10. Si H, Lu H, Yang X, Mattox A, Jang M, Bian Y, Sano E, Viadiu H, Yan B, Yau C, Ng S, Lee SK, Romano RA, Davis S, Walker RL, Xiao W, Sun H, Wei L, Sinha S, Benz CC, Stuart JM, Meltzer PS, Van Waes C, Chen Z. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer. Oncogene. 2016 Nov 03; 35(44):5781-5794.
    View on PubMed
  11. Esserman L, Yau C. Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply. JAMA Oncol. 2016 Mar 1; 2(3):395-6.
    View on PubMed
  12. Olow A, Chen Z, Niedner RH, Wolf DM, Yau C, Pankov A, Lee EP, Brown-Swigart L, van 't Veer LJ, Coppé JP. An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res. 2016 Apr 1; 76(7):1733-45.
    View on PubMed
  13. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, Van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30.
    View on PubMed
  14. Yau C, Meyer L, Benz S, Vaske C, Scott G, Egan B, Labhart P, Pourmand N, Benz CC. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index. Breast Cancer Res Treat. 2015 Nov; 154(1):23-32.
    View on PubMed
  15. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015 Oct 8; 163(2):506-19.
    View on PubMed
  16. Esserman L, Yau C. Rethinking the Standard for Ductal Carcinoma In Situ Treatment. JAMA Oncol. 2015 Oct 1; 1(7):881-3.
    View on PubMed
  17. Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R. DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep. 2015 Sep; 16(9):1219-32.
    View on PubMed
  18. Mockus M, Prebil L, Ereman R, Dollbaum C, Powell M, Yau C, Benz CC. First Pregnancy Characteristics, Postmenopausal Breast Density, and Salivary Sex Hormone Levels in a Population at High Risk for Breast Cancer. BBA Clin. 2015 Jun; 3:189-195.
    View on PubMed
  19. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015; 17:73.
    View on PubMed
  20. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 1; 21(13):2911-5.
    View on PubMed

Go to UCSF Profiles, powered by CTSI